VolitionRx Limited

About VolitionRx Limited

Volition is dedicated to revolutionizing the diagnosis and monitoring of life-altering diseases such as cancer and sepsis through the advancement of epigenetic science. Their mission is to save lives and improve outcomes for millions of people and animals worldwide by developing innovative, cost-effective, and accessible blood tests for early disease detection and monitoring.

Products & Services

Nu.Q® NETs:A CE-marked diagnostic solution for clinicians to detect NETosis, aiding in the identification of related conditions.

Nu.Q® Vet Cancer Test:An affordable and accessible blood test designed to detect cancer in dogs.

Nu.Q® Discover:A program offering advanced assays for rapid epigenetic profiling, used in disease model development, preclinical testing, and clinical studies.

Nu.Q® Cancer:A range of blood-based assays under development with potential applications beyond cancer detection.

Capture-PCR™:A novel method for liquid biopsy enabling rapid, cost-effective cancer detection through routine blood tests.

Specialties

Epigenetics Nucleosome Quantification Early Disease Detection Cancer Diagnostics Sepsis Diagnostics Veterinary Diagnostics

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Debt T: - FT: Debt	A: 2000000 MR: - FA: $2,000,000 FAN: 2000000	D: 2026-01-08 FD: 2026-01-08	1 investors
2	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 6000000 MR: - FA: 6.0 million FAN: 6000000	D: 2025-10-10 FD: 2025-10-10	1 investors
3	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 1210000 MR: - FA: $1.21 million FAN: 1210000	D: 2025-08-04 FD: 2025-08-04	2 investors
4	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 2300000 MR: - FA: up to $2.3 million FAN: 2300000	D: 2025-03-26 FD: 2025-03-26	3 investors
5	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 1900000 MR: - FA: up to $1.9 million FAN: 1900000	D: 2024-12-06 FD: 2024-12-06	2 investors
6	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 7000000 MR: - FA: $7 million FAN: 7000000	D: 2024-08-09 FD: 2024-08-09	-
7	RT: Debt and Equity T: - FT: Debt and Equity	A: 5500000 MR: - FA: Euro 5.0 million FAN: 5500000	D: 2023-12-05 FD: 2023-12-05	1 investors
8	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 19000000 MR: - FA: approximately $19.0 million FAN: 19000000	D: 2023-06-23 FD: 2023-06-23	2 investors
9	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 16500000 MR: - FA: approximately $16.5 million FAN: 16500000	D: 2023-06-05 FD: 2023-06-05	2 investors
10	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 16500000 MR: - FA: $16.5 million FAN: 16500000	D: 2023-06-01 FD: 2023-06-01	2 investors
11	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 8700000 MR: - FA: approximately $8.7 million FAN: 8700000	D: 2023-02-22 FD: 2023-02-22	1 investors
12	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 7525000 MR: - FA: 7.525 million FAN: 7525000	D: 2023-02-17 FD: 2023-02-17	1 investors

Debt Latest

2026-01-08

$2.0M

1 investor (Pro only)

Underwritten Public Offering 2025-10-10

$6.0M

Registered Direct Offering 2025-08-04

$1.2M

View 11 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jake Micallef

Chief Scientific Officer

M

Mark Eccleston

Scientific Advisor

C

Cameron Reynolds

President & Group Chief Executive Officer

T

Terig Hughes

Group Chief Financial Officer

G

Gaetan Michel

Chief Operating Officer

N

Nick Plummer

Group General Counsel

View 19 more team members with Pro

Unlock Full Team Directory

Recent News